Lower extremity peripheral arterial disease in individuals with coronary artery disease: Prognostic importance, care gaps, and impact of therapy

American Heart Journal

Volumn 155, Issue 2, 2008, Pages 348-355

  Makowsky, Mark J ^a   McAlister, Finlay A ^a,b   Galbraith, P Diane ^c   Southern, Danielle A ^c   Ghali, William A ^d   Knudtson, Merril L ^d   Tsuyuki, Ross T ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

^b UNIVERSITY OF ALBERTA   (Canada)

^c UNIVERSITY OF CALGARY   (Canada)

^d UNIVERSITY OF CALGARY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; AGED; ANGIOCARDIOGRAPHY; ARTERY DISEASE; ARTICLE; CANADA; CLINICAL TRIAL; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DISEASE SEVERITY; EVIDENCE BASED MEDICINE; FEMALE; FOLLOW UP; HUMAN; LEG DISEASE; MAJOR CLINICAL STUDY; MALE; MORTALITY; PATIENT CARE; PRIORITY JOURNAL; PROGNOSIS; TREATMENT OUTCOME;

AGED; CARDIOVASCULAR AGENTS; CORONARY ARTERY DISEASE; FEMALE; HUMANS; LOWER EXTREMITY; MALE; MIDDLE AGED; PERIPHERAL VASCULAR DISEASES; PROGNOSIS; PROSPECTIVE STUDIES;

EID: 38349086384     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2007.09.005     Document Type: Article

References (44)

1. Belch J.J.F., Topol E.J., Agnelli G., et al. Critical issues in peripheral arterial disease detection and management: a call to action. Arch Intern Med 163 (2003) 884-892
2. Hirsch A.T., Criqui M.H., Treat-Jacobson D., et al. Peripheral arterial disease detection, awareness, and treatment in primary care. JAMA 286 (2001) 1317-1324
3. Bhatt D.L., Steg P.G., Ohman E.M., et al. International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. JAMA 295 (2006) 180-189
4. Steg P.G., Bhatt D.L., Wilson P.W., et al. One-year cardiovascular event rates in outpatients with atherothrombosis. JAMA 297 (2007) 1197-1206
5. Hirsch A., Haskal Z., Hertzer N., et al. ACC/AHA guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): executive summary: a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease [Lower Extremity, Renal, Mesenteric, and Abdominal Aortic]). J Am Coll Cardiol 47 (2006) e1-e192
6. Abramson B.L., Huckell V., Anand S., et al. Canadian Cardiovascular Society Consensus Conference: peripheral arterial disease-executive summary. Can J Cardiol 21 (2005) 997-1006
7. McDermott M.M., Mehta S., Ahn H., et al. Atherosclerotic risk factors are less intensively treated in patients with peripheral arterial disease than in patients with coronary artery disease. J Gen Intern Med 12 (1997) 209-215
8. Eagle K.A., Rihal C.S., Foster E.D., et al. Long-term survival in patients with coronary artery disease: importance of peripheral vascular disease. The Coronary Artery Surgery Study (CASS) Investigators. J Am Coll Cardiol 23 (1994) 1091-1095
9. Sutton-Tyrrell K., Rihal C., Sellers M.A., et al. Long-term prognostic value of clinically evident noncoronary vascular disease in patients undergoing coronary revascularization in the Bypass Angioplasty Revascularization Investigation (BARI). Am J Cardiol 81 (1998) 375-381
10. Rihal C.S., Sutton-Tyrrell K., Guo P., et al. Increased incidence of periprocedural complications among patients with peripheral vascular disease undergoing myocardial revascularization in the bypass angioplasty revascularization investigation. Circulation 100 (1999) 171-177
11. Cotter G., Cannon C.P., McCabe C.H., et al. Prior peripheral arterial disease and cerebrovascular disease are independent predictors of adverse outcome in patients with acute coronary syndromes: are we doing enough? Results from the Orbofiban in Patients with Unstable Coronary Syndromes-Thrombolysis In Myocardial Infarction (OPUS-TIMI) 16 study. Am Heart J 145 (2003) 622-627
12. Nallamothu B.K., Chetcuti S., Mukherjee D., et al. Long-term prognostic implication of extracardiac vascular disease in patients undergoing percutaneous coronary intervention. Am J Cardiol. 92 (2003) 964-966
13. O'Rourke D.J., Quinton H.B., Piper W., et al. Survival in patients with peripheral vascular disease after percutaneous coronary intervention and coronary artery bypass graft surgery. Ann Thorac Surg 78 (2004) 466-470 [discussion 470]
14. Singh M., Lennon R.J., Darbar D., et al. Effect of peripheral arterial disease in patients undergoing percutaneous coronary intervention with intracoronary stents. Mayo Clin Proc 79 (2004) 1113-1118
15. Saw J., Bhatt D.L., Moliterno D.J., et al. The influence of peripheral arterial disease on outcomes: a pooled analysis of mortality in eight large randomized percutaneous coronary intervention trials. J Am Coll Cardiol 48 (2006) 1567-1572
16. Chiu J.H., Topol E.J., Whitlow P.L., et al. Peripheral vascular disease and one-year mortality following percutaneous coronary revascularization. Am J Cardiol 92 (2003) 582-583
17. Nikolsky E., Mehran R., Dangas G.D., et al. Prognostic significance of cerebrovascular and peripheral arterial disease in patients having percutaneous coronary interventions. Am J Cardiol 93 (2004) 1536-1539
18. Froehlich J.B., Mukherjee D., Avezum A., et al. Association of peripheral artery disease with treatment and outcomes in acute coronary syndromes. The Global Registry of Acute Coronary Events (GRACE). Am Heart J 151 (2006) 1123-1128
19. Ghali W.A., and Knudtson M.L. Overview of the Alberta Provincial Project for Outcome Assessment in Coronary Heart Disease. On behalf of the APPROACH investigators. Can J Cardiol 16 (2000) 1225-1230
20. Nieto F.J., and Coresh J. Adjusting survival curves for confounders: a review and a new method. Am J Epidemiol 143 (1996) 1059-1068
21. Ghali W.A., Quan H., Brant R., et al. Comparison of 2 methods for calculating adjusted survival curves from proportional hazards models. JAMA 286 (2001) 1494-1497
22. Smith G.D., Shipley M.J., and Rose G. Intermittent claudication, heart disease risk factors, and mortality. The Whitehall Study. Circulation 82 (1990) 1925-1931
23. Dagenais G.R., Maurice S., Robitaille N.M., et al. Intermittent claudication in Quebec men from 1974-1986: the Quebec Cardiovascular Study. Clin Invest Med 14 (1991) 93-100
24. McKenna M., Wolfson S., and Kuller L. The ratio of ankle and arm arterial pressure as an independent predictor of mortality. Atherosclerosis 87 (1991) 119-128
25. Criqui M.H., Langer R.D., Fronek A., et al. Mortality over a period of 10 years in patients with peripheral arterial disease. N Engl J Med 326 (1992) 381-386
26. Vogt M.T., Cauley J.A., Newman A.B., et al. Decreased ankle/arm blood pressure index and mortality in elderly women. JAMA 270 (1993) 465-469
27. Newman A.B., Sutton-Tyrrell K., Vogt M.T., et al. Morbidity and mortality in hypertensive adults with a low ankle/arm blood pressure index. JAMA 270 (1993) 487-489
28. Kornitzer M., Dramaix M., Sobolski J., et al. Ankle/arm pressure index in asymptomatic middle-aged males: an independent predictor of ten-year coronary heart disease mortality. Angiology 46 (1995) 211-219
29. Leng G.C., Fowkes F.G., Lee A.J., et al. Use of ankle brachial pressure index to predict cardiovascular events and death: a cohort study. BMJ 313 (1996) 1440-1444
30. Newman A.B., Tyrrell K.S., and Kuller L.H. Mortality over four years in SHEP participants with a low ankle-arm index. J Am Geriatr Soc 45 (1997) 1472-1478
31. Bowlin S.J., Medalie J.H., Flocke S.A., et al. Intermittent claudication in 8343 men and 21-year specific mortality follow-up. Ann Epidemiol 7 (1997) 180-187
32. Newman A.B., Shemanski L., Manolio T.A., et al. Ankle-arm index as a predictor of cardiovascular disease and mortality in the Cardiovascular Health Study. The Cardiovascular Health Study Group. Arterioscler Thromb Vasc Biol 19 (1999) 538-545
33. Hooi J.D., Kester A.D., Stoffers H.E., et al. Asymptomatic peripheral arterial occlusive disease predicted cardiovascular morbidity and mortality in a 7-year follow-up study. J Clin Epidemiol 57 (2004) 294-300
34. Burek K.A., Sutton-Tyrrell K., Brooks M.M., et al. Prognostic importance of lower extremity arterial disease in patients undergoing coronary revascularization in the Bypass Angioplasty Revascularization Investigation (BARI). J Am Coll Cardiol 34 (1999) 716-721
35. Birkmeyer J.D., O'Connor G.T., Quinton H.B., et al. The effect of peripheral vascular disease on in-hospital mortality rates with coronary artery bypass surgery. Northern New England Cardiovascular Disease Study Group. J Vasc Surg 21 (1995) 445-452
36. Birkmeyer J.D., Quinton H.B., O'Connor N.J., et al. The effect of peripheral vascular disease on long-term mortality after coronary artery bypass surgery. Northern New England Cardiovascular Disease Study Group. Arch Surg 131 (1996) 316-321
37. Loponen P., Taskinen P., Laakkonen E., et al. Peripheral vascular disease as predictor of outcome after coronary artery bypass grafting. Scand J Surg 91 (2002) 160-165
38. Nikolsky E., Mehran R., Mintz G.S., et al. Impact of symptomatic peripheral arterial disease on 1-year mortality in patients undergoing percutaneous coronary interventions. J Endovasc Ther 11 (2004) 60-70
39. Rihal C.S., Eagle K.A., Mickel M.C., et al. Surgical therapy for coronary artery disease among patients with combined coronary artery and peripheral vascular disease. Circulation 91 (1995) 46-53
40. Varnauskas E. Twelve-year follow-up of survival in the randomized European Coronary Surgery Study. N Engl J Med 319 (1988) 332-337
41. Gibbons R.J., Abrams J., Chatterjee K., et al. ACC/AHA 2002 guideline update for the management of patients with chronic stable angina-summary article: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines (Committee on the Management of Patients With Chronic Stable Angina). J Am Coll Cardiol 41 (2003) 159-168
42. Radack K., and Deck C. Beta-adrenergic blocker therapy does not worsen intermittent claudication in subjects with peripheral arterial disease. A meta-analysis of randomized controlled trials. Arch Intern Med 151 (1991) 1769-1776
43. Newby L.K., Allen LaPointe N.M., Chen A.Y., et al. Long-term adherence to evidence-based secondary prevention therapies in coronary artery disease. Circulation 113 (2006) 203-212
44. McAlister F.A., Fradette M., Graham M., et al. A randomized trial to assess the impact of opinion leader endorsed evidence summaries on the use of secondary prevention strategies in patients with coronary artery disease : the ESP-CAD Trial protocol. BMC Implement Sci 1 (2006) 11